Alpha Cognition (ACOG) 10% Owner Inc. Buys $191K of Stock
Key Points
- Opaleye Management purchased 22,657 shares of Alpha Cognition Inc. at an average price of $8.43 on October 15, 2026, totaling roughly $190,974.
- After the trade, Opaleye Management Inc. indirectly holds 3,245,611 $ACOG shares, up 0.70% from before the trade.
- The biopharmaceutical firm recently traded around $8.50, sitting 5.4% below its 50-day moving average and 20.9% above its 200-day moving average.
- Wall Street analysts maintain a consensus strong buy rating on the stock with a mean price target of $18.00 across five analyst opinions.
Since the trade, $ACOG is up 0.6% to date (from the $8.45 close on Oct 15, 2026).
Get Alpha Cognition text alerts
We text you when insiders, Congress, analysts or big funds move on $ACOG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alpha Cognition Inc. alert may contain errors. Disclosures
Opaleye Management bought 22,657 shares of Alpha Cognition Inc. (ACOG) on October 15, 2026, adding to its sizable position in the biotechnology firm. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.
ACOG
Alpha Cognition Inc.
Opaleye Management Inc. vs. the S&P 500
Hypothetical returns from Opaleye Management Inc.'s disclosed trades, not real profit or advice. How we model this.
Inside Opaleye Management's Alpha Cognition Trade
The 10% owner acquired the shares at an average price of $8.43, spending a total of $190,973.59 on the purchase. Following the transaction, Opaleye Management held 3,245,611 shares of Alpha Cognition, representing a 0.7% increase in its holdings.
Other Institutional Activity in Alpha Cognition
Solas Capital Management, LLC held 1,924,617 shares worth about $16,359,244 with no unit change reported. AWM Investment Company, Inc. held 1,672,168 shares valued at roughly $14,213,428. Cable Car Capital, LP maintained its position with 1,382,339 shares worth about $11,749,881. Ikarian Capital, LLC reduced its holdings by 220,024 shares, ending with 836,259 shares valued at about $7,108,201.
Alpha Cognition Inc. Stock Up 3.8%
The stock recently traded around $8.50 as of October 19, 2026. That puts the shares 16.2% below their 52-week high of $10.14 and 88.9% above their 52-week low of $4.50. The company carries a market capitalization of $185.1 million.
Recent Earnings
Alpha Cognition reported trailing-twelve-month revenue of $15,260,706 with a revenue growth year-over-year of 267.6%. The company posted a trailing-twelve-month basic earnings per share loss of $1.32, alongside a net margin of -137.7% and a return on equity of -49.5%. The next earnings report is scheduled for November 12, 2026.
Insider Buying and Selling at Alpha Cognition Inc.
Opaleye Management previously picked up 52,900 shares on August 3, 2026, followed by 123,918 shares on September 16, 2026, and 31,763 shares on September 25, 2026. Director Robert James Wills also bought 10,000 shares on August 21, 2026, at an average price of $9.62 for a total value of $96,200.
Analysts Set New Price Targets
Raymond James initiated coverage on July 10, 2026, with an outperform rating and a $20.00 price target. HC Wainwright & Co. maintained a buy rating on August 17, 2026, while lifting its price target from $18.00 to $20.00. B. Riley Securities initiated an explicit buy rating with a $21.00 target on August 20, 2026.
About Alpha Cognition
Alpha Cognition is a biopharmaceutical company based in Grapevine, Texas, focused on treatments for neurodegenerative conditions. Its lead development program features the ZUNVEYL oral tablet designed to treat Alzheimer's disease.
Bottom Line
Opaleye continues to build its stake while the market awaits Alpha Cognition's next earnings update on November 12, 2026. Observers will monitor whether other institutional backers adjust their positions ahead of upcoming clinical milestones.
Related Filing Alerts
Source: Opaleye Management Inc.'s Form 4 filing on $ACOG (Oct 15, 2026). Written by software, not financial advice. How we make alerts